Deep-pocketed investors have taken a bullish approach towards$吉利德科学(GILD.US)$, Benzinga reported, cited nine extraordinary options activities linked to the stock. About 77% of the trades were leaning bullish and 22% bearish, according to the report. Four of them were puts, totaling $495,628, and five were calls, amounting to $213,111, the report showed. The volume and open interest data on the contract...
$SPDR标普生物科技ETF(XBI.US)$$生物科技指数ETF-iShares(IBB.US)$ M&A in Q1 alone totaled 12 deals for $19.2 bil which is close to the 10 deals for $21.9 bil in all the 1H of 2023... But one big caveat of this chart, it doesn't include$辉瑞(PFE.US)$'s $43 bil deal for $SGEN announced in Mar 2023 but didn't close until Dec bc of an FTC challenge, The biggest biotech M&A deal so far this yr was$吉利德科学(GILD.US)$'s $4.3 b...
On March 29,$吉利德科学(GILD.US)$and$Xilio Therapeutics(XLO.US)$' announced that they have reached an exclusive license agreement totaling more than 600 million US dollars. Here's a look at some technical analysis:
+4
4
2
举报
Pumpui :
Just buy and hold. The gilead news is worth it. Plus any breakthru in cancer treatment for biohealth will be huge. I am holding
Rockaphobic楼主Pumpui:
Absolutely! I can't help but feel a bit of confidence. With such promising news, coupled with the fact that Vanguard is one of the 52 institutional shareholders. Sign me up! GL!
Gilead Sciences' dividend seems sustainable but flat earnings and high payout could limit future growth. There may be more attractive dividend prospects elsewhere.
The development and marketing of ADCs are likely to significantly benefit the bottom lines of pharmaceutical and biotech companies involved in their production. Companies like ImmunoGen and ADC Therapeutics are also highlighted as ones to watch in the ADC space.
GILD's share price pullback to near 52-week lows could be a buying opportunity. Analysts predict a 5.1% annual earnings growth in the next five years, with a 19.8% upside potential from current levels.
吉利德科学股票讨论区
加载中...
Gilead Sciences Sees Deep-Pocketed Investors Take Bullish Stance, Benzinga Reports
Four of them were puts, totaling $495,628, and five were calls, amounting to $213,111, the report showed. The volume and open interest data on the contract...
要去一趟66甚至60了
12 Biotech M&A deals in Q1 totaling $19 bil on similar pace with 2022...
M&A in Q1 alone totaled 12 deals for $19.2 bil which is close to the 10 deals for $21.9 bil in all the 1H of 2023...
But one big caveat of this chart, it doesn't include $辉瑞(PFE.US)$ 's $43 bil deal for $SGEN announced in Mar 2023 but didn't close until Dec bc of an FTC challenge,
The biggest biotech M&A deal so far this yr was $吉利德科学(GILD.US)$ 's $4.3 b...
Moderate + Growth. Aiming for dividend stocks before entering growth stocks.
Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:
$默沙东(MRK.US)$ x $Immunovant(IMVT.US)$
$礼来(LLY.US)$ x $Cytokinetics(CYTK.US)$ (and soon)
$再生元制药公司(REGN.US)$ x $Apellis Pharmaceuticals(APLS.US)$ (panache & brash)
$吉利德科学(GILD.US)$ x %$Madrigal Pharmaceuticals(MDGL.US)$ (liver king)
$施贵宝(BMY.US)$ x $Iovance Biotherapeutics(IOVA.US)$ (cell Tx boost needed)
$礼来(LLY.US)$ x $Merus(MRUS.US)$ (partner n...
New Pivot Point
Here's a look at some technical analysis:
暂无评论